Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29906404 | 1.00 | HSD17B10 (0.60) | HSD17B10LMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL27796780 | 0.86 | HSD17B10 (0.56) | HSD17B10LMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL508763 | 0.85 | HSD17B10 (0.60) | HSD17B10LMNASMN1; SMN2ALDH1A1VCAM1 | |
| SCHEMBL29672035 | 0.85 | HSD17B10 (0.60) | HSD17B10LMNASMN1; SMN2ALDH1A1VCAM1 | |
| SCHEMBL863249 | 0.83 | HSD17B10 (0.62) | HSD17B10LMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL13241715 | 0.83 | HSD17B10 (0.62) | HSD17B10LMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL260864 | 0.82 | CYP1A2 (0.47) | HSD17B10LMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL29368452 | 0.82 | CYP1A2 (0.47) | HSD17B10LMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2182437 | 0.81 | HSD17B10 (0.60) | HSD17B10LMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL8262558 | 0.81 | HSD17B10 (0.60) | HSD17B10LMNASMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066364-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2025-02-27 | — | — | US | disclosed |
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| EP-4406616-A2 | SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2024-07-31 | — | — | EP | disclosed |
| US-20240174589-A1 | PHOTOREDOX RADICAL BENZYLATION PROCESS | CENTRE NAT RECH SCIENT (FR) | 2024-05-30 | — | — | US | disclosed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-11932645-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | Bial—R & D Investments, S.A. (PT) | 2024-03-19 | — | — | US | disclosed |
| EP-4301722-A1 | PHOTOREDOX RADICAL BENZYLATION PROCESS | Centre National de la Recherche Scientifique (FR) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023143135-A1 | QUINAZOLINE DERIVATIVE AND USE THEREOF | 赛诺哈勃药业（成都）有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-116514728-A | Quinazoline derivative and application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2005092858-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST | PFIZER JAPAN INC. (JP) | 2005-10-06 | — | — | WO | disclosed |
| EP-1545523-A1 | 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS | Astex Technology Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005002673-A1 | RAF KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| EP-0798292-B1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | CHUGAI SEIYAKUKABUSHIKI KAISHA (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2004004720-A1 | 3-`(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES AS P38 MAP KINASE INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
| US-6534546-B1 | Guanidine- or isothioureido-N-derived anilines; brain, nervous system, and neurodegenerative disorders | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-18 | — | — | US | disclosed |
| CN-1310169-A | Anils with nitric oxide synzyme inhibiting function | SHUGAI SEIYAKU K K (JP) | 2001-08-29 | — | — | CN | disclosed |
| CN-1172473-A | Aniline derivatives having nitric oxide synthase inhibitory activity | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1998-02-04 | — | — | CN | disclosed |
| EP-0798292-A1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 1997-10-01 | — | — | EP | disclosed |
| WO-1995000499-A1 | HERBICIDAL SUBSTITUTED 1,5-DIARYL-1H-1,2,4-TRIAZOL-3-CARBOXAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932645-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | PARK7, PNP, GAA | HSD17B10 4408/4885LMNA 1610/4885SMN1; SMN2 28/4885 |
| US-20240174589-A1 | PHOTOREDOX RADICAL BENZYLATION PROCESS | H1-2, H1-3, H1-0 | HSD17B10 825/4885LMNA 3404/4885SMN1; SMN2 4594/4885 |
| US-20250066364-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, PNP, GAA | HSD17B10 4408/4885LMNA 1610/4885SMN1; SMN2 28/4885 |
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | PNPO, PDXK, PLPBP | HSD17B10 3116/4885LMNA 2226/4885SMN1; SMN2 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.